This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Okuma, Y. et al. First-line osimertinib for previously untreated patients with NSCLC and uncommon EGFR mutations: the UNICORN phase 2 nonrandomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2023.5013 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romero, D. Patients with uncommon EGFR mutations also benefit from first-line osimertinib. Nat Rev Clin Oncol 21, 84 (2024). https://doi.org/10.1038/s41571-023-00847-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00847-x